You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 664 A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
664 A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to August 2024

AbstractFullPdf
Nov 2022300025
Dec 20226809
Jan 20235405
Feb 20235605
Mar 20236803
Apr 20236201
May 20235203
Jun 2023802
Jul 20232606
Aug 20233803
Sep 2023802
Oct 20232601
Nov 20232403
Dec 20235603
Jan 20241601
Feb 20241604
Mar 20242002
Apr 202440010
May 20242802
Jun 20242407
Jul 20243406
Aug 20241805
Total10420108